Literature DB >> 19636198

Cardiovascular risk factors in primary hyperparathyroidism.

R Luboshitzky1, Y Chertok-Schaham, I Lavi, A Ishay.   

Abstract

BACKGROUND AND AIMS: Severe primary hyperparathyroidism (PHP) has been associated with increased cardiovascular morbidity. Such an association in mild PHP is not known. We conducted a cross-sectional study to assess the correlation between mild and traditional PHP and emergent cardiovascular risk factors. SUBJECTS AND METHODS: A total of 139 patients with PHP (72 with severe PHP and indications for parathyroidectomy, 67 with mild PHP and no indications for surgery) and 111 control subjects, of similar age and body weight, were enrolled in this study. Participants had measurement of fasting blood levels of calcium, PTH, insulin, glucose, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, interleukin-6, and C-reactive protein. Body mass index (BMI), waist and hip circumferences, blood pressure, homeostasis model assessment 2-insulin resistance index (IR) and the presence of metabolic syndrome (MS) were evaluated.
RESULTS: Severe PHP patients had significantly higher rates of MS (37.5%), IR (38.9 %) vs mild PHP (34.3 and 23.9%, respectively) and controls (14.4 and 14.4%, respectively). Multivariate logistic-regression model, adjusted for age and BMI, and for age and waist size, revealed that severe PHP had significantly higher likelihood of cardiovascular risks [odds ratio (OR) 3.5, 95% confidence interval (CI) 1.5-8.125, p=0.004 for MS, and OR 3.7, 95% CI 1.64-8.29, p=0.002 for IR]. Serum calcium significantly predicted the presence of MS (OR 1.875, 95% CI 1.259-2.793, p=0.002) and IR (OR 2.043, 95% CI 1.365-3.057, p=0.002).
CONCLUSIONS: Greater probability of MS and insulin resistance was observed in patients with severe PHP. Serum calcium is a predictor of these cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19636198     DOI: 10.1007/BF03345719

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  24 in total

Review 1.  Use and abuse of HOMA modeling.

Authors:  Tara M Wallace; Jonathan C Levy; David R Matthews
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

2.  Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.

Authors:  Stefan Blankenberg; Matthew J McQueen; Marek Smieja; Janice Pogue; Cynthia Balion; Eva Lonn; Hans J Rupprecht; Christoph Bickel; Laurence Tiret; Francois Cambien; Hertzel Gerstein; Thomas Münzel; Salim Yusuf
Journal:  Circulation       Date:  2006-07-10       Impact factor: 29.690

3.  Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study.

Authors:  Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Leonelo Bautista; Maria Grazia Franzosi; Patrick Commerford; Chim C Lang; Zvonko Rumboldt; Churchill L Onen; Liu Lisheng; Supachai Tanomsup; Paul Wangai; Fahad Razak; Arya M Sharma; Sonia S Anand
Journal:  Lancet       Date:  2005-11-05       Impact factor: 79.321

4.  Urate and arteriosclerosis in primary hyperparathyroidism.

Authors:  J Westerdahl; S Valdemarsson; P Lindblom; A Bergenfelz
Journal:  Clin Endocrinol (Oxf)       Date:  2001-06       Impact factor: 3.478

5.  Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism.

Authors:  Christina Gerlach Ogard; Mads D Engelmann; Caroline Kistorp; Steen Levin Nielsen; Henrik Vestergaard
Journal:  Clin Endocrinol (Oxf)       Date:  2005-11       Impact factor: 3.478

6.  Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption--a clinical research center study.

Authors:  A Grey; M A Mitnick; S Shapses; A Ellison; C Gundberg; K Insogna
Journal:  J Clin Endocrinol Metab       Date:  1996-10       Impact factor: 5.958

7.  Cardiac dysfunction in mild primary hyperparathyroidism assessed by radionuclide angiography and echocardiography before and after parathyroidectomy.

Authors:  Erik G Almqvist; Anne-Greth Bondeson; Lennart Bondeson; Anders Nissborg; Peter Smedgård; Sven-Eric Svensson
Journal:  Surgery       Date:  2002-12       Impact factor: 3.982

8.  Case-control study on symptoms and signs of "asymptomatic" primary hyperparathyroidism.

Authors:  E Lundgren; S Ljunghall; G Akerström; J Hetta; H Mallmin; J Rastad
Journal:  Surgery       Date:  1998-12       Impact factor: 3.982

9.  Insulin secretion, insulin sensitivity and hepatic insulin extraction in primary hyperparathyroidism before and after surgery.

Authors:  A Kautzky-Willer; G Pacini; B Niederle; G Schernthaner; R Prager
Journal:  Clin Endocrinol (Oxf)       Date:  1992-08       Impact factor: 3.478

10.  Body weight and bone mineral density in postmenopausal women with primary hyperparathyroidism.

Authors:  A B Grey; M C Evans; J P Stapleton; I R Reid
Journal:  Ann Intern Med       Date:  1994-11-15       Impact factor: 25.391

View more
  9 in total

1.  Acute hyperparathyroidism and vascular thrombosis; an unrecognized association.

Authors:  A Franchello; M Camandona; G Gasparri
Journal:  J Endocrinol Invest       Date:  2010-10       Impact factor: 4.256

2.  Hyperparathyroidism, an emerging disease.

Authors:  Guido Gasparri; Nicola Palestini; Silvia Catalano; Francesca Talarico; Clemente Ronchetta; Gregorio Balbo; Michele Camandona
Journal:  Updates Surg       Date:  2010-11-13

3.  Parathyroidectomy Decreases Insulin Resistance Index in Patients with Primary Hyperparathyroidism.

Authors:  Cevdet Duran; Barıs Sevinc; Orkide Kutlu; Omer Karahan
Journal:  Indian J Surg       Date:  2016-01-15       Impact factor: 0.656

4.  Prevalence and characteristics of metabolic syndrome in primary hyperparathyroidism.

Authors:  F Tassone; L Gianotti; C Baffoni; F Cesario; G Magro; M Pellegrino; I Emmolo; M Maccario; G Borretta
Journal:  J Endocrinol Invest       Date:  2011-12-21       Impact factor: 4.256

5.  Cardiac structure and diastolic function in mild primary hyperparathyroidism.

Authors:  M D Walker; J B Fleischer; M R Di Tullio; S Homma; T Rundek; E M Stein; C Zhang; T Taggart; D J McMahon; S J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2010-03-12       Impact factor: 5.958

6.  Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms.

Authors:  M Procopio; M Barale; S Bertaina; S Sigrist; R Mazzetti; M Loiacono; G Mengozzi; E Ghigo; M Maccario
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

7.  Increased frequency of impaired fasting glucose and isolated systolic hypertension in Paget's disease of bone.

Authors:  Marco Barale; Vincenzo Cappiello; Ezio Ghigo; Massimo Procopio
Journal:  Endocrine       Date:  2018-10-03       Impact factor: 3.633

Review 8.  Nontraditional manifestations of primary hyperparathyroidism.

Authors:  Marcella Donovan Walker; Mishaela Rubin; Shonni J Silverberg
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

9.  Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism.

Authors:  Selvihan Beysel; Mustafa Caliskan; Muhammed Kizilgul; Mahmut Apaydin; Seyfullah Kan; Mustafa Ozbek; Erman Cakal
Journal:  BMC Cardiovasc Disord       Date:  2019-05-08       Impact factor: 2.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.